Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial

Published:2016-12 Issue:6 Volume:65 Page:1112-1119
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Sperl Jan,Horvath Gabor,Halota Waldemar,Ruiz-Tapiador Juan Arenas,Streinu-Cercel Anca,Jancoriene Ligita,Werling Klara,Kileng Hege,Koklu Seyfettin,Gerstoft Jan,Urbanek Petr,Flisiak Robert,Leiva Rafael,Kazenaite Edita,Prinzing Renate,Patel Sushma,Qiu Jingjun,Asante-Appiah Ernest,Wahl Janice,Nguyen Bach-Yen,Barr Eliav,Platt Heather L.

Publisher

Elsevier BV

Subject

Hepatology

Reference21 articles.

1. Global epidemiology of hepatitis C virus infection;Shepard;Lancet Infect Dis,2005

2. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with Hepatitis C virus;Hepatology,2015

3. EASL recommendations on treatment of hepatitis C 2015;J Hepatol,2015

4. Hepatitis C in the interferon-free era;Streinu-Cercel;Germs,2013

5. Zepatier [package insert],2016

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological Impact of Type I Interferon Dysregulation;Rare Neurodegenerative Disorders - New Insights [Working Title];2024-07-31

2. Fibrosis Regression Post Direct-acting Antiviral Treatment in Hepatitis C Virus Patients;Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy;2023-03-23

3. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States;JAMA Network Open;2022-12-07

4. Concordance between Patients and Clinicians for Reporting Symptoms Associated with Treatment for Chronic Hepatitis C during a Pragmatic Clinical Trial;GastroHep;2022-07-04

5. Retrospective multicentre study on the effectiveness of first‐line direct‐acting antivirals against hepatitis C virus genotype‐1;Journal of Clinical Pharmacy and Therapeutics;2022-02-28